Меню
Набор скоро начнётся NCT06672770

Effect of Functional Inspiratory Muscle Training in Patients with Multiple Sclerosis

Без фазы С лечением Core Muscles Functional Inspiratory Muscle Training Multiple Sclerosis Respiratory Muscles

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Functional Inspiratory Muscle Training, Basic Inspiratory Muscle Training.
Кому может быть актуально
Состояния в реестре: Core Muscles, Functional Inspiratory Muscle Training, Multiple Sclerosis, Respiratory Muscles. Базовые параметры: 18 лет — 65 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Turkey (Türkiye)
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Investigation of the Effects of Functional Inspiratory Muscle Training on Respiratory Muscle Strength, Functional Exercise Capacity and Cognitive Function in Patients with Multiple Sclerosis

Обзор

This study aims to investigate the effects of functional inspiratory muscle training, basic inspiratory muscle training and physical activity in addition to respiratory exercises on respiratory muscle strength, respiratory function, cognition, walking, balance, functional exercise capacity, physical activity, quality of life and core muscles in volunteer Multiple Sclerosis (MS) patients. This study is planned as a prospective, randomized and experimental study.

Подробное описание

Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system and is a chronic and progressive disease characterized by inflammation, demyelination, and axonal degeneration. Due to axonal damage and demyelination, various neurological findings with motor and sensory losses are observed in patients with MS depending on their localization in the central nervous system. These findings vary depending on the location and size of the lesion, frequency, and severity of the disease. It is known that there are 2.8 million people living with MS in the world. Generally, the first symptoms appear between the ages of 20-40, but it is defined as early-onset or pediatric under the age of 18, adult-onset between the ages of 18-49, and late-onset after the age of 50. It is approximately twice as common in women, and is more common between the ages of 20-50, especially in white races. Although four clinical types are defined in MS: relapsing remitting MS, primary progressive MS, secondary progressive MS, relapsing progressive MS, clinically isolated MS has been added to the current classification, and the relapsing progressive MS classification has been abolished and those in this classification have been included in the primary progressive MS class. The relapsing remitting type is the most common, and there are periods of exacerbation (relapse) and remission in this type. Complications that occur during the exacerbation period show full or near-full recovery during the remission period. Various neurological findings such as spasticity, muscle weakness, gait disturbance, cognitive impairment, swallowing problems, bladder-bowel dysfunction can be observed in MS patients, and respiratory complications constitute one of the most common and important causes of death in MS. The risk of death is almost 12 times higher due to respiratory complications, which constitute approximately 47% of the causes of death in MS. Involvement of the pulmonary system, which is usually observed to have deterioration in diffusion capacity, respiratory muscle strength, and ventilation-perfusion ratio, leads to exercise intolerance, hospitalization, and mortality in MS. In MS, the primary factor is the formation of demyelinating plaques in the central nervous system, and the secondary factors include medications used, fatigue due to the disease, increased body temperature, a sedentary lifestyle, and loss of fitness, which all come together to cause pulmonary effects such as respiratory muscle weakness, lung volume deterioration, neurogenic pulmonary edema, sleep-disordered breathing, impaired respiratory control, decreased coughing efficiency, and respiratory failure. When the literature is examined, it seems that there is a need to try new methods in these disease groups to prevent respiratory complications and improve respiration due to pulmonary effects seen in MS. This study aims to investigate the effects of functional inspiratory muscle training, basic inspiratory muscle training, and physical activity applied in addition to respiratory exercises on respiratory muscle strength, respiratory function, cognitive function, walking, balance, functional exercise capacity, physical activity, quality of life, and core muscles in patients with Relapsing Remitting type Multiple Sclerosis.

Вмешательства

  • Другое Functional Inspiratory Muscle Training
    The functional inspiratory muscle training group will perform basic inspiratory muscle training in the first four weeks of the study and the following exercises with the Powerbreath device in muscle training in the following four weeks: 1. Diaphragmatic breathing exercises 2. Warm-up exercises 3. Trunk strength and lumbopelvic stability exercises 4. Dynamic trunk exercises 5. Postural control exercises 6. Cool-down exercises
  • Другое Basic Inspiratory Muscle Training
    The basic inspiratory muscle training group will do muscle training with the POWERbreathe device for eight weeks.

Первичные конечные точки

  • Inspiratory Respiratory Muscle Strength [Срок оценки: 8 weeks]
  • Expiratory Respiratory Muscle Strength [Срок оценки: 8 weeks]
  • Respiratory Function (FEV₁) [Срок оценки: 8 weeks]
  • Respiratory Function (FVC) [Срок оценки: 8 weeks]
  • Respiratory Function (FEV₁/FVC) [Срок оценки: 8 weeks]
  • Respiratory Function (PEF) [Срок оценки: 8 weeks]
  • Respiratory Function (FEF%25-75) [Срок оценки: 8 weeks]
  • Respiratory Function (VC) [Срок оценки: 8 weeks]
  • Paced Auditory Serial Addition Test (PASAT) [Срок оценки: 8 weeks]
  • Symbol Digit Modalities Test (SDMT) [Срок оценки: 8 weeks]

Критерии участия

Критерии включения

  • Diagnosed with Relapsing Remitting Type Multiple Sclerosis (RRMS),
  • EDSS (Expanded Disability Status Scale in MS: EDSS) score ranging from 1-5,
  • Able to communicate (speak, understand, read and understand Turkish),
  • Individuals who have not had an attack in the last three months,
  • Individuals who have not received respiratory-based rehabilitation in the last six months will be included in the study.

Критерии исключения

  • Those with neurological diseases other than MS,
  • Those who have functional exercise restrictions,
  • Those with chronic cardiac or pulmonary diseases such as chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease and heart failure that may affect respiratory muscle strength and respiratory functions,
  • Individuals who have had pneumonia due to viral or bacterial infection in the last six months or COVID-19 positive individuals proven by PCR-RT,
  • Those with orthopedic problems, persistent neck and back pain and/or radiculopathy that prevent them from participating in the study,
  • Those with diagnosed psychiatric disorders,
  • Those who use tobacco and tobacco products,
  • Participants with cooperation problems that may prevent evaluations and treatment will not be included in the study.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Turkey (Türkiye) · 1 центр
  • Selcuk University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitat — Konya

Публикации

  • Tong TK, Wu S, Nie J. Sport-specific endurance plank test for evaluation of global core muscle function. Phys Ther Sport. 2014 Feb;15(1):58-63. doi: 10.1016/j.ptsp.2013.03.003. Epub 2013 Jul 11. PMID 23850461
  • Simeoni M, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constantinescu C, Idiman E, Boyko A, Beiske A, Vollmer T, Triantafyllou N, O'Connor P, Barak Y, Biermann L, Cristiano E, Atweh S, Patrick D, Robitail S, Ammoury N, Beresniak A, Pelletier J; MusiQol study group. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult Scler. 2008 Mar;14(2):219-30. doi: 10.11 PMID 17942521
  • Shubert TE, Schrodt LA, Mercer VS, Busby-Whitehead J, Giuliani CA. Are scores on balance screening tests associated with mobility in older adults? J Geriatr Phys Ther. 2006;29(1):35-9. PMID 16630375
  • Savcı, F. D. S., Öztürk, U. F. M., & Arıkan, F. D. H. (2006). Üniversite öğrencilerinin fiziksel aktivite düzeyleri. Türk Kardiyol Dern Arfl, 34(3), 166-172.
  • Saglam M, Arikan H, Savci S, Inal-Ince D, Bosnak-Guclu M, Karabulut E, Tokgozoglu L. International physical activity questionnaire: reliability and validity of the Turkish version. Percept Mot Skills. 2010 Aug;111(1):278-84. doi: 10.2466/06.08.PMS.111.4.278-284. PMID 21058606
  • Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948-68. doi: 10.1183/09031936.05.00035205. No abstract available. PMID 16264058
  • Neder JA, Andreoni S, Lerario MC, Nery LE. Reference values for lung function tests. II. Maximal respiratory pressures and voluntary ventilation. Braz J Med Biol Res. 1999 Jun;32(6):719-27. doi: 10.1590/s0100-879x1999000600007. PMID 10412550
  • Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available. PMID 16055882

Идентификаторы

NCT: NCT06672770 · SelcukU_PT_MS_FIMT-IMT_Resp.01

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗